STOCKSCREENR
Log In

STOK

NASDAQ

Stoke Therapeutics, Inc.

$32.87-1.09(-3.21%)Mkt Cap: $1.88B

Key Stats

Market Cap

$1.88B

P/E Ratio

49.80

EPS

$0.66

Dividend Yield

0.00%

52-Week Range

$5.35 — $40.22

Volume

655.30K

Avg Volume

755.08K

Beta

1.19

Valuation

P/E (TTM)

49.80

Forward P/E

—

PEG Ratio

-2.77

P/S (TTM)

10.64

P/B (TTM)

7.29

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

0.13%

ROA (TTM)

0.11%

ROIC

—

Gross Margin

1.00%

Operating Margin

0.13%

Net Margin

—

Debt/Equity

0.01

Current Ratio

6.53

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

+0.09%

EPS Growth (5Y)

-0.04%

Sales Growth (3Y)

+0.96%

Sales Growth (5Y)

+0.57%

EPS Est (This Year)

$-3.14

EPS Est (Next Year)

$-2.78

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$4.24

Analyst Consensus

Price Target Range

$35.00$38.00$60.00
LowMedianHigh

Consensus Target: $42.75(30.1% upside)

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

0

Outstanding Shares

57.12M

Float

44.51M

Free Float %

77.93%

About

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

IPO Date

2019-06-19

Employees

128

CEO

Ian F. Smith

Index Membership

—

Website

https://www.stoketherapeutics.com

Stoke Therapeutics, Inc. (STOK) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $1.88B, a P/E ratio of 49.80, STOK is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare STOK against other stocks using dozens of fundamental and technical filters.

Similar Stocks

CYBN

Cybin Inc.

$8.28

+1.22%

$413.02M

BTX

BlackRock Technology and Private Equity Term Trust

$6.49

+1.56%

$757.45M

BHVN

Biohaven Ltd.

$9.53

-1.14%

$1.01B

VKTX

Viking Therapeutics, Inc.

$35.53

-1.33%

$4.11B

SNDX

Syndax Pharmaceuticals, Inc.

$23.77

-1.12%

$2.10B

ARDX

Ardelyx, Inc.

$5.83

-0.17%

$1.43B

Frequently Asked Questions

What is Stoke Therapeutics, Inc.'s P/E ratio?

Stoke Therapeutics, Inc. (STOK) has a trailing twelve-month (TTM) P/E ratio of 49.80. This is above the market average, which may reflect high growth expectations or premium valuation. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Stoke Therapeutics, Inc. pay a dividend?

No, Stoke Therapeutics, Inc. (STOK) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Stoke Therapeutics, Inc.'s market cap?

Stoke Therapeutics, Inc. (STOK) has a market capitalization of $1.88 billion, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.